VOLUME 17 | NUMBER 7 | JULY 2011 nAture medicine Individuals suffering from nerve injury or those undergoing treatment for cancer or AIDS can experience persistent pain that is resistant to commonly used analgesics. Some conditions of severe intractable clinical pain necessitate intrathecal delivery of Prialt (Azur Pharma, also known as ziconotide), a synthetic ω-conotoxin that blocks neuronal calcium channels. The clinical efficacy of Prialt has identified the N-type Ca 2+ channel (CaV2.2) as a key target for the treatment of chronic pain [1] [2] [3] [4] . However, the use of Prialt for pain management is limited by its method of delivery, narrow therapeutic window and adverse effects such as hypotension and memory loss 1,4 . The discovery of new small-molecule inhibitors of CaV2.2 for use as analgesics may lead to improved therapeutic pharmacology. CRMP-2 is a modulator of CaV2.2 (refs. 5, 6) . It is a cytosolic phosphoprotein that was originally identified as a mediator of growth cone collapse 7 that can also modify axon number, length 8 and neuronal polarity 9-11 . CRMP-2 interacts with CaV2.2, and overexpression of CRMP-2 leads to increased surface expression of CaV2.2, enhanced Ca 2+ currents and an increase in stimulated release of calcitonin gene-related peptide (CGRP) from dorsal root ganglia (DRG) 5, 6 . By contrast, knockdown of CRMP-2 markedly reduces Ca 2+ currents and transmitter release 5, 6 . Here we report that uncoupling the interaction between CRMP-2 and CaV2.2 led to a physiologically relevant decrease in Ca 2+ current and neurotransmitter release (Supplementary Fig. 1a ) and suppressed persistent inflammatory and neuropathic hypersensitivity.
Immunoprecipitations from rat spinal cord lysates showed that CBD3 inhibited the interaction between CRMP-2 and CaV2.2 but did not affect the interaction between tubulin and CRMP-2 (ref. 12 ; Fig. 1b) . As CRMP-2 binds the first intracellular loop (L1) and the distal C terminus (Ct-dis) of CaV2.2 (ref. 5) , we investigated whether CBD3 bound these regions. We used surface plasmon resonance to show that CBD3, but not a scrambled peptide, bound immobilized L1 and Ct-dis (Fig. 1c) . Moreover, the CBD3 peptide disrupted the interaction between CRMP-2 and the L1 or Ct-dis regions ( Fig. 1d and Supplementary Fig. 1b,c) .
Because CRMP-2 facilitates trafficking of CaV2.2 to the surface 5, 6 , we tested whether CBD3 could uncouple CRMP-2 from CaV2.2 to affect the trafficking, surface expression and activity of CaV2.2, as well as Ca 2+ influx. Expression of both CaV2.2 and CBD3 in the CAD neuronal cell line 13 resulted in almost complete retention of the channel in cytoplasmic aggregates ( Fig. 1e-g ). Surface biotinylation in CAD cells showed that the expression of CBD3, but not of scrambled peptide or CBD1, prevented the surface expression of co-expressed CaV2.2 (Fig. 1h) . Furthermore, expression of CRMP-2 with CBD3 in rat hippocampal neurons eliminated the CRMP-2-mediated increase in CaV2.2 current density 5 (Fig. 1i,j) and the expression of CBD3, but not of a scrambled control peptide, reduced depolarization-induced calcium influx in hippocampal neurons ( Supplementary Fig. 2a-c) . Thus, in vitro, CBD3 disrupts the interaction between CRMP-2 and CaV2.2, decreases the plasma membrane trafficking of CaV2.2 and reduces Ca 2+ current density.
We fused CBD3 with the transduction domain of the HIV-1 TAT protein 14 to generate the cell-permeant TAT-CBD3, which readily entered DRG neurons (Fig. 2a) . Application of TAT-CBD3 to DRGs for 15 min reduced Ca 2+ currents by ~60% (Fig. 2b) , and currents were not further blocked by addition of the CaV2.2 blocker ω-conotoxin GVIA (1 µM; Fig. 2c,d) ; this suggests that TAT-CBD3 is selective for N-type channels. We obtained qualitatively similar results from calcium imaging in rat DRGs: TAT-CBD3 reduced K + -evoked Ca 2+ influx selectively through N-type channels (Supplementary Fig. 2d ). TAT-CDB3 did not affect sodium current density or gating in DRGs (Supplementary Fig. 3 ).
To determine whether uncoupling CRMP-2 from CaV2.2 with TAT-CBD3 modulates synaptic transmission, we used patch-clamp recording in spinal cord slices to measure synaptic responses in mouse lamina II neurons (Fig. 2e,f) that received input from C-fiber primary afferents expressing CaV2. 2 (refs. 15,16) . The spontaneous excitatory postsynaptic currents (sEPSCs) in these neurons are caused by glutamate release and reflect presynaptic and postsynaptic mechanisms (frequency change and amplitude change, respectively) 17 . Perfusion of mouse spinal cord slices with TAT-CBD3 reduced the frequency of sEPSCs by 57% without changing their amplitudes, supporting the idea that it has a presynaptic action (Fig. 2f) . By contrast, the control TAT-Scramble had no effect on eEPSC frequency (Fig. 2e,f) . Recordings from layer V pyramidal neurons in cortical brain slices also showed that TAT-CBD3 reduced the probability of glutamate release from stimulated presynaptic terminals (Supplementary Fig. 4 ).
TAT-CBD3 reduces evoked CGRP release Calcium entry through presynaptic CaV2.2 on small-diameter sensory neurons 18, 19 is directly coupled to transmitter release 20, 21 . Consequently, we investigated whether TAT-CBD3 could modulate the release of immunoreactive CGRP (iCGRP) from dissociated mouse DRG neurons treated with 10 µM of peptide. Pretreatment with TAT-CBD3, but not with TAT-Scramble, for 20 min or 12 h reduced the CGRP release evoked by 50 mM potassium chloride without affecting resting release ( Supplementary Fig. 5a-d) . Furthermore, total CGRP content was unaffected by the peptides. Cell viability, measured after 12 h incubation, was not affected by any treatments (Supplementary Fig. 5 ).
We next examined the effect of TAT-CBD3 on capsaicin-evoked release of CGRP from rat spinal cord slices. This release occurs primarily from the central terminals of neurons that express the transient receptor potential vanilloid type 1 (TRPV1) channel 22 , which is important for pain transduction. Perfusion with peptides did not change basal iCGRP release (Fig. 3a,b) . However, perfusion with 20 µM (but not 10 µM; Supplementary Fig. 5e ,f) of TAT-CBD3 led to a decrease in capsaicin-evoked iCGRP release compared to that seen in cells perfused with TAT-Scramble (Fig. 3c) . The total iCGRP content did not differ (Fig. 3d) . The fact that TAT-CBD3 had no effect on TRPV1 current recordings (peak amplitudes and activation rates) from DRG neurons (Supplementary Fig. 6 ) shows that TAT-CBD3 does not act through direct inhibition of TRPV1 channels.
TAT-CBD3 affects vasodilatation in rat dura mater in vivo
The dura mater is innervated by trigeminal, capsaicin-sensitive sensory neurons that mediate meningeal vascular responses related to headache pain 23 . As the release of CGRP from sensory nerve endings causes vasodilation, we tested the potential involvement of CRMP-2 using in vivo laser Doppler blood flowmetry in rats to measure capsaicin-induced changes in blood flow 24 (Fig. 4a) . Capsaicin induced CGRP-dependent dilation of meningeal blood vessels (Fig. 4b,c ) that faded to baseline values within minutes. Dural application of TAT-CBD3 before nasal administration of capsaicin inhibited capsaicin-induced changes in blood flow in a dose-dependent manner (Fig. 4c,d ). TAT-CBD3 alone did not alter basal blood flow: changes in blood flow without capsaicin were as follows (in tissue perfusion units): vehicle, −6 ± 1 (n = 5); TAT-Scramble, −9 ± 3 (n = 5); and TAT-CBD3, −4 ± 3 (n = 4). The capsaicin-induced blood flow changes were CGRP dependent, as they could be blocked by prior dural administration of the CGRP antagonist CGRP (Fig. 4c) . The concentration-response curve of percentage inhibition (versus averaged TAT-Scramble) of blood flow by TAT-CBD3 yielded a half-maximal inhibitory concentration of 3.1 ± 1.1 µM (Fig. 4d) .
TAT-CBD3 reduces evoked nocifensive behaviors
As the inhibition of CaV2.2 is antinociceptive 25 , we examined whether TAT-CBD3 could attenuate nociceptive responses in rat pain models. We first investigated the effects of peptides on formalin-induced nocifensive behavior. In rats that received a subcutaneous injection (to the dorsal surface of the hindpaw) of vehicle (20 µl 0.5% vol/vol DMSO) 30 min before injection of formalin (2.5% vol/vol in 50 µl), we observed the expected biphasic formalin response 26 (Fig. 5a) . Immediately after formalin injection, the rats showed a high degree of flinching (phase 1) for about 10 min followed by a second period of flinching (phase 2) which subsided by 60 min. Pretreatment with 30 or 100 µM TAT-Scramble did not change either phase of the formalin test. By contrast, rats pretreated with 30 or 100 µM TAT-CBD3 showed blunted nociceptive behaviors in both phases (Fig. 5a,b) , which suggests that TAT-CBD3 inhibits nociception mediated by direct activation of sensory neurons (phase 1) and, to some extent, nociception associated with inflammation 27 and spinal involvement (phase 2) 28, 29 . Pretreatment with 3 µM TAT-CBD3 did not affect the formalin-induced behavior (Fig. 5a,b) . Injection of peptides alone, before the formalin injection, did not induce any nocifensive behavior. Formalin (2.5%) produced a fourfold change in paw thickness (ipsilateral minus contralateral) compared to saline (Fig. 5c) , consistent with the edema that typically follows inflammation. TAT-CBD3 did not inhibit formalin-induced edema.
To determine whether TAT-CBD3 inhibits capsaicin-induced nociception, we used the capsaicin eye-wipe test. The cornea is innervated by trigeminal afferent nerves, of which ~25% express TRPV1 (refs. 30,31) . Application of TAT-CBD3 alone to the rat cornea did not induce nocifensive behavior. Pretreatment with 30 or 100 µM TAT-CBD3 for 30 min attenuated capsaicin-induced nocifensive behavior (Fig. 5d) , suggesting that TAT-CBD3 is antinociceptive at a peripheral site. Pretreatment with 3 µM TAT-CBD3 did not affect nocifensive behavior; however, 100 µM TAT-Scramble showed a nonspecific effect, increasing the nocifensive response time (Fig. 5d) .
TAT-CBD3 attenuates ddC-induced neuropathic pain behavior
We next examined the effects of the peptide on chronic nociceptive behavior in an animal model of painful neuropathy induced by AIDS therapy 32, 33 . Nucleoside reverse transcriptase inhibitors such as 2′,3′ dideoxycytidine (ddC), which are commonly used to treat AIDS, produce side effects that include painful neuropathies. We evaluated the ability of peptides to reverse tactile hypersensitivity in rats 7 d after a single injection of ddC. TAT-CBD3 alone had no effect on paw withdrawal threshold (PWT). TAT-CBD3, but not TAT-Scramble, caused a dose-dependent increase in PWT when administered intraperitoneally after ddC treatment (Fig. 5e) . Tactile hypersensitivity was completely reversed 1 h after intraperitoneal injection of 1 mg kg −1 TAT-CBD3. Four hours after injection, the TAT-CBD3-induced reversal of hypersensitivity had diminished by 50%, which may be accounted for by degradation and biodistribution of the peptide 34 . To investigate the distribution of peptides after intraperitoneal injection, we collected tissue samples from animals injected with FITC-TAT-CBD3. After the injection we detected the peptide in the DRG at 15 min (Fig. 5f-i) , spinal cord at 15 min (Fig. 6 ) and brain at 1 h (Supplementary Fig. 7a-c) . We observed transient contortions in rats injected intraperitoneally with 20 mg per kg body weight of TAT-CBD3, but not at lower doses that inhibited hypersensitivity ( Fig. 5e and Supplementary Fig. 7d-h) .
Thus, our results indicate that TAT-CBD3, which interferes with the interaction between CaV2.2 and CRMP-2, reduces acute inflammatory and neuropathic pain behaviors.
TAT-CBD3 does not cause neurobehavioral deficits
We investigated whether TAT-CBD3 had any effect on mouse motor coordination, locomotor function, sedation (rotarod test 35 ) and hippocampusdependent memory (Morris water-maze test 36, 37 ). Impaired locomotor function did not account for reduced flinching and paw withdrawal as TAT-CBD3 (10 and 50 mg per kg body weight; intraperitoneal injection) had no effect in the accelerating rotarod test (Fig. 6a) . There was also no effect of TAT-CBD3 (10 mg per kg body weight; intraperitoneal injection) on motor coordination (rotarod test) and spatial memory retrieval, as measured by the Morris water maze, between 1 h and 7 d after administration (Fig. 6b,c) . We observed a single episode of kinking at the base of the tail and whole body contortion in rats immediately after single injections of doses higher than 10 mg per kg body weight of TAT-CBD3 (Supplementary Fig. 7d-g ).
As pharmacological blockade of N-type channels has been clinically linked to anxiety and depression 38 , we tested whether TAT-CDB3 could alter these behaviors in mice using the elevated plus maze (EPM) test and light-dark box test (LDBT). These paradigms assess the conflict between hiding in enclosed dark areas (dark box or closed arm) and exploring new environments (white box or open arm) 39, 40 . In the EPM test, neither time spent in the open or closed arms nor the frequency of entries into the open or closed arms was altered by any dose of TAT-CBD3, compared to TAT-Scramble (Fig. 6h  and Supplementary Table 1) . In the LDBT, although time spent in the white and dark boxes did not differ between any of the conditions, the number of transitions between the light and dark boxes was higher in mice injected with 1 mg per kg body weight TAT-CBD3 compared to TAT-Scramble (Fig. 6i) . These results suggest that TAT-CBD3 does not affect anxiety-associated behaviors apart from increasing transitions in LDBT, supporting the idea that it may have slightly anxiolytic properties. As rodents show immobile postures when placed in inescapable, stressful situations 41 , immobility behavior in the tail suspension test (TST) or forced swim test (FST) is used as a measure of 'depression' or 'despair-associated' behavior, which is attenuated by antidepressant treatments 42 . In the TST in mice, neither time spent immobile nor the frequency of immobile episodes was altered by any dose of TAT-CBD3, compared to TAT-Scramble (Fig. 6j and Supplementary  Table 1) . Overall, no dose of TAT-CBD3 altered depression or despairassociated behavior.
DISCUSSION
Our findings show that administration of TAT-conjugated CBD3 peptide interfered with CaV2.2 trafficking to the presynaptic membrane and that treatment with TAT-CBD3 peptide inhibited calcium currents, stimulus-evoked neuropeptide release from sensory neurons and excitatory synaptic transmission in dorsal horn neurons in rats and mice. TAT-CBD3, which disrupts the enhancement of CaV2.2 function by CRMP-2, achieves a therapeutic window suitable for a number of pain states, both inflammatory and neuropathic, with no impairment of motor function or higher order processes. TAT-CBD3 seems to affect pain signaling by regulating CaV2.2.
To block interactions between CRMP-2 and the N-type calcium channel, we designed a CaV2.2-binding peptide, CBD3, which is fully conserved between rodents and humans and has little or no sequence homology with other proteins. We conjugated the peptide to the HIV-1 TAT domain to overcome the obstacle of poor plasma membrane penetrance of peptides 43, 44 .
Pharmacological block of CaV2.2 not only reduces presynaptic neurotransmitter release but also might decrease the excitability of the postsynaptic neurons in lamina I of the spinal cord 45 . The decrease in sEPSC frequency in the postsynaptic, spinal cord lamina II neurons after treatment with TAT-CBD3 may be due to both inhibition of glutamate release from sensory neurons and diminished vesicular recycling 25 .
It has been suggested that CaV2.2 instigates the increased excitability and neurotransmitter release that are associated with chronic and neuropathic pain conditions 19, 25, 45, 46 . Genetic and pharmacological block of CaV2.2 after injury in rodents attenuates nociceptive behavior 47, 48 . Moreover, expression of CaV2.2 is upregulated in several animal models of neuropathic pain 46 . Inhibition of CaV2.2 is also one mechanism of morphine-induced analgesia 49 . A pro-nociceptive role for CaV2.2 is further highlighted by the identification of alternative splice variants of CaV2.2 expressed on small-diameter nociceptive neurons 50 that contribute to thermal and mechanical hyperalgesia 51 . For these reasons, CaV2.2 has become a prime therapeutic target in the treatment of chronic pain.
To determine the effects of TAT-CBD3 on nociception, we used a variety of rat pain models that included acute and inflammatory or chronic nociception states. Behavioral outcomes from the capsaicin eye-wipe test 52 suggested that the peptide inhibited acute nociception. In addition, the administration of TAT-CBD3 into the dorsal surface of the paw significantly reduced the number of flinches in phase 1 and phase 2 of the formalin test. TAT-CBD3 had a greater effect in phase 1 of the formalin test than in phase 2, which at first may suggest that CaV2.2 has a more pronounced effect in primary nociception than in the perception of inflammatory pain. Phase 1 of the formalin test results from direct stimulation of nociceptors, whereas phase 2 involves a period of central sensitization during which inflammatory phenomena occur 53 . Therefore, because the peptide was injected in the periphery, the effect observed in phase 1 suggests that TAT-CBD3 either affects transmission of the nociceptive signal or inhibits the release of CGRP or other neuropeptides at the peripheral end of the nociceptors. The observation that the effects of TAT-CBD3 were antinociceptive in acute studies is consistent with the activity-dependent regulation that has been demonstrated for the interaction between CRMP-2 and CaV2.2 (ref. 5) , consistent with a decrease in presynaptic neuronal excitability.
As our results in other models showed that CGRP release was inhibited, we hypothesized that this could explain the effect of TAT-CBD3 in phase 1 of the formalin test. If TAT-CBD3 inhibits the peripheral release of CGRP, then one would expect a reduction in edema. However, TAT-CBD3 did not inhibit formalin-induced edema. Although the peripheral inflammatory process and its relationship to nociception are not completely understood, edema occurs in response to several inflammatory mediators that could be released by cells other than neurons. Therefore, inhibiting the release of only CGRP is probably insufficient to reduce edema. The differential effects of TAT-CBD3 on nociceptive behavior and edema suggest that these inflammatory components do not share a common mechanism. In support of this assertion, a serotonin receptor antagonist inhibits nociceptive behavior induced by 2.5% formalin but does not inhibit edema 54 . Moreover, morphine administered peripherally inhibits carrageenan-induced hyperalgesia without inhibiting edema, whereas systemically injected morphine reduced edema, plasma extravasation and inflammatory hyperalgesia 55 . Thus, although TAT-CBD3 did not inhibit formalin-induced edema, an effect on neurotransmitter release cannot be ruled out as a mechanism of its peripheral antinociceptive effect in our pain models.
In addition, we found that TAT-CBD3 suppressed tactile hypersensitivity in an animal model of HIV treatment-induced peripheral neuropathy, a chronic model of neuropathic pain. This model uses the antiretroviral treatment ddC to induce the dying-back neuropathy of small fibers that is seen in patients with AIDS after treatment, which has been attributed to reduced calcium buffering 32, 33, [56] [57] [58] . Systemic administration of TAT-CBD3 reversed ddC-induced nociceptive behaviors, suggesting that the interaction between CRMP-2 and CaV2.2 has a continued role in neurotransmitter release. Consistent with this hypothesis, CaV2.2 mediates enhanced release of neurotransmitters in the spinal cord that is important for the maintenance of inflammatory pain 59 .
Despite the potential of pharmacological inhibitors of N-type channels in the treatment of intractable or chronic pain, they have a narrow therapeutic window 25 . Intrathecal delivery of Prialt in animal and clinical studies results in a multitude of deleterious side-effects including impairments in learning and memory and motor coordination, and increased anxiety or depression 4, 19, 25, 48 . At doses more than 50-fold higher than that required to reduce hypersensitivity in vivo, TAT-CBD3 produced mild motor impairment (transient tail kinking and body contortion) but had no effect on motor coordination, memory retreival or anxiety and depression-associated behaviors in these animals. TAT-CBD3 had a mild anxiolytic effect consistent with that observed in mice lacking CaV2.2 (ref. 47) . The relative lack of toxicity observed with systemic delivery of TAT-CBD3 provides evidence that it has therapeutic promise.
From these findings, we propose that TAT-CBD3 suppresses pain hypersensitivity without directly blocking CaV2.2, but rather by inhibiting the binding of a regulator of CaV2.2 function, CRMP-2. Thus, our findings point toward an approach that might be useful for managing clinical pain.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nm/.
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